ClinicalTrials.Veeva

Menu

Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study

University Health Network, Toronto logo

University Health Network, Toronto

Status and phase

Completed
Phase 1

Conditions

Kidney Injury

Treatments

Other: Advanced red blood cell transfusion

Study type

Interventional

Funder types

Other

Identifiers

NCT00861822
08-1083-B

Details and patient eligibility

About

One of the major complications of heart surgery is kidney injury, which occurs in up to 30% of patients and is associated with poor outcomes including death. We have found that patients whose hemoglobin concentration before surgery is lower than normal (i.e., are anemic) are at particularly high risk for this complication, likely because their hemoglobin concentration drops to very low levels during surgery, which reduces delivery of oxygen to the kidneys, increases blood loss, and necessitates blood transfusions. We and others have shown that these events are individually harmful to the kidneys, and can lead to kidney injury. We believe that we can prevent these events from occurring, and as a result reduce the risk of kidney injury, if we transfuse anemic patients at least 1 day before surgery rather than during surgery.

In anemic patients undergoing cardiac surgery, prophylactic transfusion of red blood cells (RBCs) before surgery will reduce the risk of acute kidney injury (AKI) after surgery by mitigating three inter-related risk factors for AKI.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients undergoing non-emergent aortocoronary bypass (ACB) surgery, or valve surgery, combined ACB and valve, or aortic root repair requiring CPB with a preoperative Hb concentration between 100 and 120 g/L.

Exclusion criteria

  • Any conditions that may limit the ability of patients to tolerate the intervention:
  • Severe aortic or mitral valve stenosis
  • History of congestive heart failure within 30 days of surgery or severe ventricular dysfunction (ejection fraction < 30%)
  • Severe (> 60%) left main coronary artery stenosis or unstable angina within 30 days of surgery

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 2 patient groups

RBC
Active Comparator group
Description:
Advance RBC transfusion' (ART) group
Treatment:
Other: Advanced red blood cell transfusion
Standard Care
Other group
Description:
Standard-of-care RBC transfusion (SRT) group
Treatment:
Other: Advanced red blood cell transfusion

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems